Intermediate dose methotrexate (IDM) in childhood acute lymphocytic leukaemia in Norway. Report on a national treatment program.
Three courses of intermediate dose methotrexate, 500 mg/m2 at three weekly intervals have been used as part of sanctuary therapy to 95 out of 112 children with acute lymphocytic leukaemia in Norway in the period August 1975 to December 1979. Eight doses of MTX IT were also used for CNS prophylaxis, the first dose was given on the day of admission. As of July 1, 1980, 75 out of 95 (79%) were still in CCR for a median of 36 months (6-57 months).